AU2010234193B2 - Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection - Google Patents

Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection Download PDF

Info

Publication number
AU2010234193B2
AU2010234193B2 AU2010234193A AU2010234193A AU2010234193B2 AU 2010234193 B2 AU2010234193 B2 AU 2010234193B2 AU 2010234193 A AU2010234193 A AU 2010234193A AU 2010234193 A AU2010234193 A AU 2010234193A AU 2010234193 B2 AU2010234193 B2 AU 2010234193B2
Authority
AU
Australia
Prior art keywords
stec
tir
proteins
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010234193A
Other languages
English (en)
Other versions
AU2010234193A1 (en
Inventor
David Asper
Andrew A. Potter
Dragan Rogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Original Assignee
University of Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Saskatchewan filed Critical University of Saskatchewan
Publication of AU2010234193A1 publication Critical patent/AU2010234193A1/en
Application granted granted Critical
Publication of AU2010234193B2 publication Critical patent/AU2010234193B2/en
Assigned to UNIVERSITY OF SASKATCHEWAN reassignment UNIVERSITY OF SASKATCHEWAN Request for Assignment Assignors: BIONICHE LIFE SCIENCES INC., UNIVERSITY OF SASKATCHEWAN
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010234193A 2009-04-06 2010-04-06 Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection Ceased AU2010234193B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21198909P 2009-04-06 2009-04-06
US61/211,989 2009-04-06
US21660809P 2009-05-19 2009-05-19
US61/216,608 2009-05-19
PCT/CA2010/000516 WO2010115278A1 (en) 2009-04-06 2010-04-06 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection

Publications (2)

Publication Number Publication Date
AU2010234193A1 AU2010234193A1 (en) 2011-11-03
AU2010234193B2 true AU2010234193B2 (en) 2015-08-20

Family

ID=42935602

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010234193A Ceased AU2010234193B2 (en) 2009-04-06 2010-04-06 Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection

Country Status (7)

Country Link
US (1) US8734811B2 (enExample)
EP (1) EP2417165B1 (enExample)
JP (2) JP2012522522A (enExample)
AU (1) AU2010234193B2 (enExample)
BR (1) BRPI1014505B1 (enExample)
CA (1) CA2757828C (enExample)
WO (1) WO2010115278A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
KR20220007619A (ko) * 2019-05-01 2022-01-18 이네이트 바이올로직스 엘엘씨 면역조절 조성물 및 방법
EP4054655A4 (en) * 2019-11-08 2024-02-28 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
US20210369836A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
AR132724A1 (es) 2024-05-17 2025-07-23 Instituto Nac De Tecnologia Agropecuaria Inta Construcción de adn que codifica una proteína de fusión con al menos dos antígenos de escherichia coli enterohemorrágica, vectores, proteína de fusión, métodos de inmunización y vacunas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300659B2 (en) * 2001-01-04 2007-11-27 University Of Saskatchewan Enterohemorrhagic Escherichia coli vaccine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
ES2108693T3 (es) * 1990-04-05 1998-01-01 Univ Saskatchewan Compuestos y tratamientos para la neumonia en animales.
US5273889A (en) 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5238823A (en) 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
AU2699192A (en) 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ES2389625T3 (es) 1996-04-23 2012-10-29 The University Of British Columbia Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena
EP1029054B1 (en) 1997-11-12 2009-08-05 The University Of British Columbia Hp90: host membrane receptor for pathogenic bacteria, encoded by the bacterial tir gene
EP1098661A2 (en) * 1998-06-04 2001-05-16 Metamorphix, Inc. Gnrh vaccines for suppressing reproductive behavior in animals
US6365723B1 (en) 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
AU2002347314A1 (en) * 2002-11-29 2004-06-23 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
WO2007101337A1 (en) * 2006-03-06 2007-09-13 Bioniche Life Sciences Inc. Methods and compositions comprising bacterial type hi secreted proteins for mucosal immunization of animals
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300659B2 (en) * 2001-01-04 2007-11-27 University Of Saskatchewan Enterohemorrhagic Escherichia coli vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASPER, D.J. ET AL.: "Cross reactivity of enterohemorrhagic Escherichia coli O157:H7-specific sera with non-O157 serotypes", VACCINE, vol. 25, no. 49, 12 October 2007, pages 8262-8269, *
BABIUK S ET AL: "Subcutaneous and intranasal immunization with type Ill secreted proteins can prevent colonization and shedding of Escherichia coli 0157:H7 in mice", MICROBIAL PATHOGENESIS, , vol. 45, no. 1, 1 July 2008, pages 7-11, *
BRETSCHNEIDER ET AL: VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY,vol. 118, no. 3-4, 14 July 2007, pages 229-238, *

Also Published As

Publication number Publication date
BRPI1014505A2 (pt) 2016-04-05
EP2417165A4 (en) 2013-02-13
AU2010234193A1 (en) 2011-11-03
US8734811B2 (en) 2014-05-27
JP2016029049A (ja) 2016-03-03
EP2417165A1 (en) 2012-02-15
BRPI1014505A8 (pt) 2017-07-11
WO2010115278A8 (en) 2010-12-02
CA2757828A1 (en) 2010-10-14
BRPI1014505B1 (pt) 2020-02-04
EP2417165B1 (en) 2016-05-25
US20120087939A1 (en) 2012-04-12
CA2757828C (en) 2019-01-08
WO2010115278A1 (en) 2010-10-14
JP2012522522A (ja) 2012-09-27

Similar Documents

Publication Publication Date Title
Pruksakorn et al. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies.
JP5215275B2 (ja) 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
US8258280B2 (en) Plasmodium vivax hybrid circumsporozoite protein and vaccine
AU2010234193B2 (en) Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection
US7169393B2 (en) Antigenic peptide fragments of VapA protein, and uses thereof
US20140227314A1 (en) Engineered Type IV Pilin of Clostridium difficile
US6660270B2 (en) Immunization of dairy cattle with chimeric GapC protein against Streptococcus infection
US20160158333A1 (en) Methods for producing salmonella o-antigen capsules, compositions and uses thereof
CN101981052B (zh) 组合物、方法及试剂盒
EP1694697B1 (en) Surface-located campylobacter jejuni polypeptides
Singh et al. Immunogenicity assessment of Clostridium perfringens type D epsilon toxin epitope-based chimeric construct in mice and rabbit
Lun et al. Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species
JP2003515340A (ja) マイコプラズマ・ミコイデス亜種ミコイデスＳＣの抗原性タンパク質ＬｐｐＱ、その調製および使用
HK1097854B (en) Surface-located campylobacter jejuni polypeptides

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY OF SASKATCHEWAN

Free format text: FORMER APPLICANT(S): UNIVERSITY OF SASKATCHEWAN; BIONICHE LIFE SCIENCES INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 06 APR 2017 TO 06 NOV 2018 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 06 NOV 2018

MK14 Patent ceased section 143(a) (annual fees not paid) or expired